Antiangiogenic therapy of cancer by multitargeted tyrosine kinase inhibitors

被引：0
|
作者：
Agata, Naoki [1 ]
机构：
[1] Pfizer Inc, Div Med, Shibuya Ku, Tokyo 1518589, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2008年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：40P / 40P
页数：1
相关论文
共 50 条
  • [41] Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond
    Rajan, Arun
    Schrump, David S.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2015, 27 (01) : 36 - 48
  • [42] Tyrosine kinase inhibitors - An approach to cancer therapy oriented to pathogenesis
    Alves, F
    Hiddemann, W
    INTERNIST, 1997, 38 (11): : 1074 - 1082
  • [43] Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer
    Gao, Zhenzhen
    Cao, Chenxi
    Bao, Yi
    Fan, Yaohua
    Chen, Gang
    Fu, Peng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [44] Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study
    Adam Goldman
    David Bomze
    Rachel Dankner
    Dana Fourey
    Ben Boursi
    Michael Arad
    Elad Maor
    Targeted Oncology, 2021, 16 : 471 - 483
  • [45] Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study
    Goldman, Adam
    Bomze, David
    Dankner, Rachel
    Fourey, Dana
    Boursi, Ben
    Arad, Michael
    Maor, Elad
    TARGETED ONCOLOGY, 2021, 16 (04) : 471 - 483
  • [46] Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy
    Sathornsumetee, Sith
    Rich, Jeremy N.
    DRUGS OF TODAY, 2006, 42 (10) : 657 - 670
  • [47] Multitargeted tyrosine kinase inhibitors in regulation of growth and survival of acute myeloid leukemia cells
    Lasota, M.
    Balwierz, W.
    FEBS JOURNAL, 2014, 281 : 488 - 488
  • [48] Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors
    Manali Singha
    Limeng Pu
    Brent A. Stanfield
    Ifeanyi K. Uche
    Paul J. F. Rider
    Konstantin G. Kousoulas
    J. Ramanujam
    Michal Brylinski
    BMC Cancer, 22
  • [49] Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors
    Singha, Manali
    Pu, Limeng
    Stanfield, Brent A.
    Uche, Ifeanyi K.
    Rider, Paul J. F.
    Kousoulas, Konstantin G.
    Ramanujam, J.
    Brylinski, Michal
    BMC CANCER, 2022, 22 (01)
  • [50] Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors
    Liao, AT
    Chien, MB
    Shenoy, N
    Mendel, DB
    McMahon, G
    Cherrington, JM
    London, CA
    BLOOD, 2002, 100 (02) : 585 - 593
12345